Development of Carboxyfullerene Drugs to Treat ALS

治疗 ALS 的羧基富勒烯药物的开发

• 批准号: 6666951
• 负责人: JOHN M ALFORD
• 金额: $ 39.89万
• 依托单位: TDA RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-08-01 至 2005-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6666951
• 关键词: Parkinson's disease; amyotrophic lateral sclerosis; antioxidants; drug design /synthesis /production; free radical scavengers; liquid chromatography; method development; neuropharmacologic agent; neuroprotectants

DESCRIPTION (provided by applicant): Studies show that fullerene-based antioxidants make excellent neuroprotectants, and they have demonstrated good efficacy in models for a wide array of oxidative neurological disorders including arnyotrophic lateral sclerosis (ALS), Parkinson's disease and brain injury resulting from ischemic stroke. These results suggest that neuroprotective pharmaceuticals are one of the most unique, yet important and commercially viable applications of fullerenes to date. Although it shows great promise as a neuroprotectant drug useful in treating ailments such as ALS and Parkinson's disease for which better treatments are desperately needed, the derivatized fullerene compounds are currently too expensive and cannot be produced in sufficient quantities for clinical testing or to treat patients. During Phase I, we developed several new techniques that allow efficient production of a carboxyfullerene pharmaceutical compound. With continued development, we anticipate that by the completion of the project, it will be possible to economically manufacture enough of the fullerene- based neuroprotectant for clinical trials to begin.

描述（由申请人提供）：研究表明，富勒烯的抗氧化剂具有出色的神经保护剂，并且在模型中表现出良好的疗效，用于多种氧化神经系统疾病，包括砷营养性横向硬化症（ALS），帕金森氏病，帕金森氏病和脑损伤，导致缺血性疾病。这些结果表明，神经保护药是迄今为止富勒烯的最独特，但商业上可行的应用之一。 尽管作为一种神经保护剂药物显示出很大的希望，可用于治疗诸如ALS和帕金森氏病等疾病，迫切需要更好的治疗方法，但衍生化的富勒烯化合物目前过于昂贵，无法以足够的量来进行临床测试或治疗患者。在第一阶段，我们开发了几种新技术，可以有效地生产羧基化合物化合物。随着持续的发展，我们预计通过项目完成，可以在经济上生产足够的基于富勒烯的神经保护剂，以开始临床试验。